In yesterday’s Wall Street session, Jaguar Health Inc (NASDAQ:JAGX) shares traded at $0.35, down -8.75% from the previous session.
As of this writing, 1 analysts cover Jaguar Health Inc (NASDAQ:JAGX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $0.38, this indicates a potential upside of 1478.95 percent. JAGX stock price is now 3.72% away from the 50-day moving average and -73.17% away from the 200-day moving average. The market capitalization of the company currently stands at $6.70M.
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
With the price target of $5, Cantor Fitzgerald recently initiated with Overweight rating for Jaguar Health Inc (NASDAQ: JAGX).
In other news, Wolin Jonathan S., Chief of Staff, CCO & GC bought 317 shares of the company’s stock on Dec 31. The stock was bought for $10 at an average price of $0.03. Upon completion of the transaction, the Chief of Staff, CCO & GC now directly owns 6,983 shares in the company, valued at $2444.05. A total of 28.25% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in JAGX stock. A new stake in Jaguar Health Inc shares was purchased by GEODE CAPITAL MANAGEMENT, LLC during the first quarter worth $32,000. VIRTU FINANCIAL LLC invested $14,000 in shares of JAGX during the first quarter. In the first quarter, CSENGE ADVISORY GROUP acquired a new stake in Jaguar Health Inc valued at approximately $9,000. STERLING INVESTMENT ADVISORS, LTD. acquired a new stake in JAGX for approximately $7,000. CITADEL ADVISORS LLC purchased a new stake in JAGX valued at around $5,000 in the second quarter. In total, there are 17 active investors with 2.34% ownership of the company’s stock.
Wednesday morning saw Jaguar Health Inc (NASDAQ: JAGX) opened at $0.3300. During the past 12 months, Jaguar Health Inc has had a low of $0.21 and a high of $11.99. As of last week, the company has a debt-to-equity ratio of 5.61, a current ratio of 0.97, and a quick ratio of 0.69. The fifty day moving average price for JAGX is $0.3345 and a two-hundred day moving average price translates $1.2740 for the stock.
The latest earnings results from Jaguar Health Inc (NASDAQ: JAGX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.69, beating analysts’ expectations of -$1.53 by 0.84. This compares to -$8.79 EPS in the same period last year. The net profit margin was -402.00% and return on equity was -1064.36% for JAGX. The company reported revenue of $2.68 million for the quarter, compared to $2.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -8.39 percent. For the current quarter, analysts expect JAGX to generate $2.46M in revenue.
Jaguar Health Inc(JAGX) Company Profile
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
